Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Can age-distribution be an indicator of the goodness of COVID-19 testing?

View ORCID ProfileAmirhoshang Hoseinpour Dehkordi, Reza Nemati, Pouya Tavousi
doi: https://doi.org/10.1101/2020.12.21.20248690
Amirhoshang Hoseinpour Dehkordi
1School of Computer Science, Institute for Research in Fundamental Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amirhoshang Hoseinpour Dehkordi
  • For correspondence: amir.hoseinpour{at}ipm.ir
Reza Nemati
2Biotherapeutic and Medicinal Sciences, Biogen, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pouya Tavousi
3UConn Tech Park, University of Connecticut, Storrs, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

It has been evident that the faster, more accurate, and more comprehensive testing can help policymakers assess the real impact of COVID-19 and help them with when and how strict the mitigation policies should be. Nevertheless, the exact number of infected ones could not be measured due to the lack of comprehensive testing. In this paper, first of all, we will investigate the relation of transmission of COVID-19 with age by observing timed data in multiple countries. Then, we compare the COVID-19 CFR with the age-demography data. and as a result, we have proposed a method for estimating a lower bound for the number of positive cases by using the reported data on the oldest age group and the regions’ population age-distributions. The proposed estimation method improved the expected similarity between the age-distribution of positive cases and regions’ populations. Thus, using the publicly accessible data for several developed countries, we show how the improvement of testing over the course of several months has made it clear for the community that different age groups are equally prone to becoming COVID positive. The result shows that the age demography of COVID-19 gets similar to the age-demography of the population, together with the reduction of CFR over time. In addition, countries with less CFR have more similar COVID-19’s age-distribution, which is caused by more comprehensive testing, than ones who have higher CFR. This leads us to a better estimation for positive cases in different testing strategies. Having knowledge of this fact helps policymakers enforce more effective policies for controlling the spread of the virus.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

no funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not applicable

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Declarations

  • Funding Not applicable

  • Conflicts of interest/Competing interests: Not applicable

  • Availability of data and material: Not applicable

  • Code availability: Not applicable

  • Authors’ contributions: Amirhoshang Hoseinpour Dehkordi. conceived of the presented idea. All authors developed the theory and performed the computations. All authors verified the analytical methods. All authors discussed the results and contributed to the final manuscript.

Data Availability

All data are publicly available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 28, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Can age-distribution be an indicator of the goodness of COVID-19 testing?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Can age-distribution be an indicator of the goodness of COVID-19 testing?
Amirhoshang Hoseinpour Dehkordi, Reza Nemati, Pouya Tavousi
medRxiv 2020.12.21.20248690; doi: https://doi.org/10.1101/2020.12.21.20248690
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Can age-distribution be an indicator of the goodness of COVID-19 testing?
Amirhoshang Hoseinpour Dehkordi, Reza Nemati, Pouya Tavousi
medRxiv 2020.12.21.20248690; doi: https://doi.org/10.1101/2020.12.21.20248690

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)